New drug trial offers hope for Tough-to-Treat breast cancer
NCT ID NCT07299825
Summary
This study is testing whether an experimental drug called A166 can help control advanced HER2-positive breast cancer that has spread and has stopped responding to certain other targeted treatments. About 40 adults who have already tried specific cancer drugs will receive A166 through an IV every three weeks. The main goal is to see if the treatment shrinks tumors and for how long it keeps the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER-2 POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Provincial Cancer Hospital
RECRUITINGZhenzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.